Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies-Reference-Cited by-同舟云学术

Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies

Published:2017-08-31 Issue:9 Volume:30 Page:685-696
ISSN:1741-0126
Container-title:Protein Engineering, Design and Selection
language:en
Short-container-title:

Author:

Bönisch Maximilian¹,Sellmann Carolin²³,Maresch Daniel⁴,Halbig Claudia¹,Becker Stefan³,Toleikis Lars³,Hock Björn³,Rüker Florian¹

Affiliation:

1. Christian Doppler Laboratory for Antibody Engineering at Department of Chemistry and Department of Biotechnology, BOKU—University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, A-1190 Vienna, Austria

2. Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Straße 4, D-64287 Darmstadt, Germany

3. Protein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Straße 250, D-64293 Darmstadt, Germany

4. Department of Chemistry, BOKU—University of Natural Resources and Life Sciences, Vienna, Muthgasse 18, A-1190 Vienna, Austria

Funder

Christian Doppler

Merck KGaA

Austrian Science Fund

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Biochemistry,Bioengineering,Biotechnology

Link

http://academic.oup.com/peds/article-pdf/30/9/685/24351069/gzx044.pdf

Reference37 articles.

1. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling

2. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library

3. Toward the estimation of the absolute quality of individual protein structure models

4. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment;Annual Review of Chemical and Biomolecular Engineering;2024-07-24

2. RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties;mAbs;2024-03-25

3. Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows;mAbs;2024-02-21

4. Next generation of multispecific antibody engineering;Antibody Therapeutics;2023-12-08

5. Structure and Dynamics Guiding Design of Antibody Therapeutics and Vaccines;Antibodies;2023-10-18